ERBB2 and gastric cancer: Similarly, another dual CAR-NK construct targeting PD-L1 and HER2 demonstrated superior therapeutic efficacy against multiple solid tumors, including breast, ovarian, pancreatic, and gastric cancer cell lines, while minimizing immune escape through antigen loss [7] (Table 1).